Archive for May 3rd, 2012

IDRA Phase 2 trial failure. Pipeline updates for GERN CLDX NBY ONCY + SNSS news

May 03, 2012 No Comments by

Geron Corporation (Nasdaq: GERN) today announced that it has completed enrollment of its Phase 2 trial of imetelstat, as maintenance therapy following platinum-based induction therapy for patients with advanced non-small cell lung cancer (NSCLC). Top-line results are expected by before the end of 4Q 2012. Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided an update on its Phase […]

Daily News Read more

Upcoming Shareholder Meetings to vote for Reverse Splits or changes in Authorised Share counts

May 03, 2012 No Comments by

The following is a list of some companies with upcoming meetings (May – June 2012) where shareholders will be asked to vote to give permission to enforce a reverse split and/or change (usually increase) the number of authorised shares. REVERSE SPLIT VOTES: BIONOVO INC (BNVI):  May 3 – Reverse Split vote at a ratio of 1-for-250. […]

Articles Read more

ZGNX files NDA for Zohydro. Pipeline updates from AVEO VICL GERN NBIX and LGND

May 03, 2012 No Comments by

Zogenix, Inc. (NASDAQ: ZGNX) announced that it has submitted a New Drug Application (NDA) to the FDA for Zohydro for the treatment of chronic pain. AVEO Pharmaceuticals Inc.(NASDAQ: AVEO) announced preliminary data from its Phase 2 trial comparing the combination of ficlatuzumab and gefitinib to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung […]

Daily News Read more